Advertisement

Topics

Pharma Q3 Results Preview: J&J, Novartis & Roche

11:37 EDT 12 Oct 2018 | SCRIP

Investors are keen to see how J&J's Remicade is holding up to biosimilar competition, especially now that Zytiga generics are...

      

Related Stories

 

Original Article: Pharma Q3 Results Preview: J&J, Novartis & Roche

NEXT ARTICLE

More From BioPortfolio on "Pharma Q3 Results Preview: J&J, Novartis & Roche"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...